Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS.

10 Jan 2014

Cosmetic results after "lumpectomy" differ for African-American versus Caucasian women

As perceived by both patients and doctors, the cosmetic results after "lumpectomy" for breast cancer differ for African-American versus Caucasian women, suggests a pilot study in the Plastic and Reconstructive Surgery-Global Open-, the official open-access medical journal of the American Society of Plastic Surgeons (ASPS).

9 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Researchers receive $540M from Ludwig Cancer Research to accelerate research on metastasis

Cancer researchers at the University of Chicago and five other leading institutions will share equally in a $540 million gift from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig. Ludwig Cancer Research is an international community of researchers dedicated to pursuing life-changing discoveries to alter the course of cancer.

7 Jan 2014

Perioperative analgesia may improve prostate cancer outcomes

Neuraxial analgesia added to general anesthesia for radical retropubic prostatectomy may lead to improved oncologic outcomes in prostate cancer, US researchers have found.

6 Jan 2014

City of Hope to offer radiation oncology services to patients in the Arcadia area

City of Hope and Methodist Hospital of Southern California have reached an agreement in which City of Hope will acquire the hospital's radiation oncology service in Arcadia. The acquisition will expand access to City of Hope's renowned expertise in radiation therapy and will provide additional convenience for patients seeking specialized cancer services.

2 Jan 2014

China's Health Department of the People's Liberation Army orders clinical solutions from Elekta

To help manage the growing incidence of cancer, China's Health Department of the People's Liberation Army has ordered a comprehensive range of clinical solutions from Elekta. Fourteen hospitals around the country will receive in total 15 linear accelerators (linacs).

From Elekta 2 Jan 2014

Innovative therapy offers new hope to breast cancer patients

A novel breast-cancer therapy that partially reverses the cancerous state in cultured breast tumor cells and prevents cancer development in mice, could one day provide a new way to treat early stages of the disease without resorting to surgery, chemotherapy or radiation, a multi-institutional team led by researchers from the Wyss Institute of Biologically Inspired Engineering at Harvard University reported January 1 in Science Translational Medicine.

2 Jan 2014

Surgery offers better survival, functional outcomes than chemotherapy for patients with tongue cancer

Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

27 Dec 2013

RaySearch receives 2 orders for RayStation treatment planning system from proton treatment centers

RaySearch Laboratories AB has received two orders for its RayStation® treatment planning system from the proton treatment centers Seattle ProCure Management LLC in Seattle, Washington, and Princeton ProCure Management LLC in Princeton, New Jersey. The two centers will use RayStation® for treatment planning of proton radiation therapy.

23 Dec 2013

Researchers start first cancer operation room with navigator

A team of researchers from Gregorio Marañón Hospital, the company GMV and the Universidad Carlos III de Madrid (UC3M) have started the first cancer operation room with a navigator. This image-guided system will allow for increased intraoperative radiotherapy safety.

22 Dec 2013

CNAO Foundation places order for RayStation treatment planning system

RaySearch Laboratories AB has received an order for its RayStation® treatment planning system from CNAO Foundation (Centro Nazionale di Adroterapia Oncologica) in Pavia, Italy.

20 Dec 2013

RaySearch Laboratories, TomoTherapy terminate software licensing and development agreement

In 2007, RaySearch Laboratories AB and TomoTherapy Incorporated (now Accuray) entered into a software licensing and development agreement. Under the agreement, RaySearch developed a product named SharePlan, which was launched by TomoTherapy in 2009.

20 Dec 2013

New study aims to identify breast cancer patients most susceptible to post-treatment fatigue

Although the prevalence and impact of cancer-related fatigue has been well established, very little is known about its predictors, mechanisms for development, and persistence post-treatment. A new research study at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in partnership with UCLA, is aimed at identifying breast cancer patients most susceptible to post-treatment fatigue by measuring biological, behavioral and social risk factors.

19 Dec 2013

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

Elekta and McLaren Health Care to launch MOSAIQ oncology information system

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ® oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

Pelvic radiation therapy to treat uterine cancer may increase risk of developing bladder cancer

Radiation therapy used to treat uterine cancer may increase a patient's risk of developing bladder cancer. That is the conclusion of a recent study published in BJU International.

18 Dec 2013

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013

Experimental drug that targets macrophages decreases cancer's growth

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013

Nucletron installs first Esteya electronic brachytherapy system for skin cancer treatment

The first Esteya electronic brachytherapy system in the United States has been installed at New York's Memorial Sloan-Kettering Cancer Center. Esteya by Nucletron, an Elekta company, is a new approach for skin cancer treatment that relies on a small, high dose rate (HDR) X-ray source to apply high precision radiotherapy directly to the cancer site.

From Elekta 16 Dec 2013